Why did Phase 1/2 FTO solid tumour clinical trial ($8.0 million) get the nod for the base case over Cardio-protection Phase 2b clinical trial in breast cancer patients ($7.5 million)?
I understand the FTO opportunity was discovered earlier, but recent commentary suggests cardio-protection is easier to recruit for and quicker to market all going well.
I hope the full case gets funded, and I think it will. I am taking up my allocation.
Why did Phase 1/2 FTO solid tumour clinical trial ($8.0 million)...
-
- There are more pages in this discussion • 157 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.65 |
Change
0.050(3.13%) |
Mkt cap ! $281.1M | |||
| Open | High | Low | Value | Volume |
| $1.63 | $1.70 | $1.52 | $318.0K | 193.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 496 | $1.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.70 | 5484 | 2 |
View Market Depth
| Last trade - 16.10pm 28/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |